V. Mahavni

CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer

R. Buller, J. P. Geisler, W. Ju, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer

R. Buller, J. P. Geisler, W. Ju, 2005, International Journal of Gynecologic Cancer.

Hormone replacement therapy and cancer risk

A. Sood, V. Mahavni, 2001, Current opinion in oncology.

Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer

Tong-Yuan Yang, R. Buller, B. Hutchins, 2003, Cancer Gene Therapy.

Allopathic and complementary alternatives to hormone replacement therapy

A. Sood, V. Mahavni, A. Eichholz, 2002, Expert opinion on pharmacotherapy.

Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500

B. Karlan, R. Kreienberg, D. Slamon, 2002, Cancer Gene Therapy.

Estrogen replacement therapy in endometrial and breast cancer survivors.

R. Buller, V. Mahavni, 1999, Clinical obstetrics and gynecology.

The androgen receptor and DXS15-134 markers show a high rate of discordance for germline X chromosome inactivation

R. Buller, S. C. Kim, V. Mahavni, 2001, Journal of medical genetics.

Pseudoxanthoma elasticum: evidence for the existence of a pseudogene highly homologous to the ABCC6 gene

M. Upadhyaya, V. Mahavni, D. Ravine, 2001 .